Ultragenyx Pharmaceutical Inc. Class Action: Levi &
Levi & Korsinsky, LLP is reminding investors of Ultragenyx Pharmaceutical Inc. about a pending class action lawsuit with a lead plaintiff deadline of April 6, 2026. The lawsuit alleges securities fraud between August 3, 2023, and December 26, 2025, due to misleading statements regarding the potential of setrusumab, which led to a significant stock price drop after Phase III studies failed to meet primary endpoints. Investors who suffered losses during this period may be entitled to compensation without out-of-pocket costs.
ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ:RARE) Investors of the April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm
Bragar Eagel & Squire, P.C. announced that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) regarding alleged materially false and misleading statements concerning its Phase III Orbit and Cosmic Studies. Investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025, are urged to contact the firm by the April 6, 2026, lead plaintiff deadline if they suffered losses. The lawsuit stems from a significant stock drop after Ultragenyx announced its studies did not achieve statistical significance for reducing fracture rates.
FinancialContent - RARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
Faruqi & Faruqi, LLP is reminding investors of Ultragenyx Pharmaceutical (NASDAQ: RARE) about the April 6, 2026, deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Ultragenyx and its executives made misleading statements regarding the effectiveness of setrusumab for Osteogenesis Imperfecta, particularly concerning the Phase III Orbit and Cosmic studies, which ultimately failed to meet primary endpoints. Investors who purchased Ultragenyx securities between August 3, 2023, and December 26, 2025, and suffered losses are encouraged to contact the law firm.
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) for alleged securities fraud. The lawsuit claims Ultragenyx made misleading statements regarding its Osteogenesis Imperfecta drug candidate, particularly after its Phase III ORBIT study failed to show a statistically significant reduction in annualized fracture rate. Investors who purchased Ultragenyx securities between August 3, 2023, and December 26, 2025, are encouraged to contact the firm to potentially lead the lawsuit.
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has announced a class action securities lawsuit against Ultragenyx Pharmaceutical Inc. (RARE) on behalf of investors who suffered losses due to alleged securities fraud between August 3, 2023, and December 26, 2025. This follows a significant drop in Ultragenyx's share price after its Phase 3 Orbit and Cosmic studies for setrusumab failed to meet their primary endpoints. Investors have until April 6, 2026, to apply for lead plaintiff status.
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm
A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and some of its officers, alleging violations of federal securities laws. The lawsuit claims that Ultragenyx made false and misleading statements regarding its Phase III Orbit study results for setrusumab, particularly concerning the annualized fracture rate for patients with Osteogenesis Imperfecta. Investors who purchased Ultragenyx securities between August 3, 2023, and December 26, 2025, are encouraged to join the case, with a lead plaintiff deadline of April 6, 2026.
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) on behalf of investors who purchased securities between August 3, 2023, and December 26, 2025. The lawsuit alleges that Ultragenyx made misleading statements about the reliability of its Phase III Orbit study for setrusumab, particularly regarding its ability to reduce annualized fracture rates in Osteogenesis Imperfecta patients. Investors who suffered losses are encouraged to seek legal representation.
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (RARE) alleging securities fraud due to misleading statements about its drug setrusumab's efficacy. Investors who purchased RARE common stock between August 3, 2023, and December 26, 2025, are affected, with a lead plaintiff deadline of April 6, 2026. The lawsuit stems from a significant stock drop after Ultragenyx announced its Phase III trials for setrusumab failed to meet primary endpoints.
Aberdeen Group plc Buys 496,295 Shares of Ultragenyx Pharmaceutical Inc. $RARE
Aberdeen Group plc significantly increased its stake in Ultragenyx Pharmaceutical Inc. by 51% in Q4, acquiring an additional 496,295 shares, bringing its total to 1,469,951 shares valued at approximately $33.8 million. This comes as the FDA accepted the BLA resubmission for UX111, potentially improving pipeline valuation, although insider selling and ongoing securities class action solicitations present potential headwinds for the stock. Analysts currently hold a "Moderate Buy" consensus rating for Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has received a consensus "Moderate Buy" recommendation from eighteen brokerages, with an average 12-month target price of $60.47. Analysts are divided on valuation, as the company faces a pending FDA review for its gene therapy UX111, alongside risks such as a class-action lawsuit solicitation and significant insider selling. Despite recent revenue growth, the company continues to report negative profitability and missed its latest EPS estimate.
RARE SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
Faruqi & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and reminds investors of the April 6, 2026 deadline to seek lead plaintiff status in a federal securities class action. The lawsuit alleges that Ultragenyx made misleading statements and failed to disclose risks regarding its Phase III Orbit and Cosmic studies for Osteogenesis Imperfecta (OI), leading to significant stock price drops when study failures were announced. Investors who purchased Ultragenyx securities between August 3, 2023, and December 26, 2025, are encouraged to contact the law firm.
Ultragenyx 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
Kahn Swick & Foti, LLC (KSF) is reminding investors of Ultragenyx Pharmaceutical Inc. (RARE) who suffered losses exceeding $100,000 that they have until April 6, 2026, to file as lead plaintiff in a class action lawsuit. The lawsuit alleges that Ultragenyx and its executives failed to disclose material information between August 3, 2023, and December 26, 2025, leading to a significant stock price drop after the company announced failed Phase 3 studies for setrusumab. Investors who purchased securities during this period are encouraged to contact KSF to discuss their legal rights.
Ultragenyx (RARE) CFO sells 4,683 shares, retains 80,351 stake
Ultragenyx Pharmaceutical Inc.'s CFO, Howard Horn, sold 4,683 shares of common stock at $20.97 per share in an open-market transaction. Following this sale, Horn directly holds 80,351 shares, which include restricted stock units. This transaction was disclosed in a Form 4 filing and is part of a 10b5-1 plan.
RARE Deadline: Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
The Rosen Law Firm is reminding Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) investors about a class action lawsuit filed on behalf of those who purchased common stock between August 3, 2023, and December 26, 2025. The lawsuit alleges that Ultragenyx made misleading statements regarding the potential of its drug setrusumab and the likelihood of success for its Phase III studies. Investors with losses exceeding $100,000 are urged to contact the firm, with a lead plaintiff deadline of April 6, 2026.
RARE Deadline: Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
The Rosen Law Firm is reminding stockholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) who suffered losses exceeding $100,000 to contact the firm regarding a class action lawsuit. The lawsuit alleges that Ultragenyx made false or misleading statements about the potential of its drug setrusumab and the integrity of its clinical trials. Investors who wish to serve as lead plaintiff must file their motion with the court by April 6, 2026.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE
Pomerantz LLP has filed a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) on behalf of investors who suffered losses. The lawsuit alleges securities fraud, citing significant stock price drops after the company announced failures in its Phase 3 Orbit and Cosmic Studies for UX143 (setrusumab). Investors who purchased Ultragenyx securities during the Class Period have until April 6, 2026, to seek appointment as Lead Plaintiff.
Insider Selling: Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells 4,683 Shares of Stock
Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Howard Horn sold 4,683 shares of company stock for a total of $98,202.51 on April 1, under a pre-arranged Rule 10b5-1 plan, reducing his stake by 5.51%. The sale comes amidst positive clinical trial results for one of Ultragenyx's experimental therapies but also ongoing class-action lawsuits and recent downward revisions in analyst price targets, though the stock's consensus rating remains a "Moderate Buy."
Pomerantz LLP Notifies Investors of Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. – RARE
Pomerantz LLP has announced a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for alleged securities fraud or unlawful business practices. Investors who purchased Ultragenyx securities during the Class Period have until April 6, 2026, to seek to be appointed as Lead Plaintiff. The lawsuit stems from significant stock price drops following negative study results for two of Ultragenyx's Phase 3 trials in July and December 2025.
Leerink reiterates Ultragenyx stock rating on gene therapy progress
Leerink Partners reiterated an Outperform rating and a $60.00 price target for Ultragenyx Pharma (NASDAQ: RARE) after the FDA accepted the resubmitted Biologics License Application for UX111, a gene therapy for Sanfilippo Syndrome Type A. The approval of UX111, which has a PDUFA action date of September 19, 2026, could lead to two gene therapy approvals for Ultragenyx in 2026 and generate peak sales of $150 million. The company's stock currently trades at $21.93, with InvestingPro analysis indicating it is undervalued relative to its Fair Value.
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
ClaimsFiler is reminding investors of Ultragenyx Pharmaceutical Inc. (RARE) that they have until April 6, 2026, to file as lead plaintiff in a securities class action lawsuit. This lawsuit alleges that Ultragenyx failed to disclose material information between August 3, 2023, and December 26, 2025, leading to a significant stock price drop after negative Phase 3 study results were announced. Investors who suffered losses exceeding $100,000 are encouraged to contact ClaimsFiler or Kahn Swick & Foti, LLC for legal options.
Ultragenyx BLA for UX111 Accepted for FDA Review
Ultragenyx Pharmaceutical announced that the FDA has accepted for review its resubmitted Biologics License Application (BLA) for UX111, a gene therapy for Sanfilippo syndrome Type A (MPS IIIA). The application is seeking accelerated approval, with a PDUFA action date set for September 19, 2026. This regulatory milestone could significantly advance treatment options for this rare genetic disorder.
Ultragenyx (RARE) gets FDA review date for UX111 gene therapy on Sept. 19, 2026
Ultragenyx Pharmaceutical Inc. announced that the FDA has accepted its resubmitted Biologics License Application for UX111, an AAV9 gene therapy for Sanfilippo syndrome Type A (MPS IIIA). The application is seeking accelerated approval, and the FDA has set a Prescription Drug User Fee Act (PDUFA) action date of September 19, 2026, for a decision. The company acknowledged inherent risks concerning clinical data sufficiency, manufacturing readiness, and potential safety issues.
Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
Ultragenyx Pharmaceutical Inc. announced that the U.S. FDA has accepted for review its resubmitted Biologics License Application (BLA) for UX111 (rebisufligene etisparvovec) AAV9 gene therapy to treat Sanfilippo syndrome Type A (MPS IIIA). If approved, UX111 would be the first therapy for this rare, neurodegenerative disease. The FDA has set a PDUFA action date of September 19, 2026.
Howard Horn sells multiple RARE shares (NASDAQ: RARE) under Form 144
Howard Horn reported multiple sales of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock under a Form 144 notice. The filing details five dispositions between January 2, 2026, and March 3, 2026, with individual share amounts and gross proceeds for each sale. These transactions involved restricted or performance-based shares originating from the issuer, with the largest single disposition being 5,290 shares for $120,616.98 on March 2, 2026.
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026
Kahn Swick & Foti, LLC (KSF) has announced a class action securities lawsuit against Ultragenyx Pharmaceutical Inc. (NasdaqGS: RARE) for investors who suffered losses between August 3, 2023, and December 26, 2025. This follows Ultragenyx's December 2025 announcement that its Phase 3 Orbit and Cosmic studies failed to meet primary endpoints, leading to a significant stock price drop. Investors have until April 6, 2026, to apply to be lead plaintiff.
Ultragenyx Pharmaceutical Reports FDA Acceptance of IND Application for UX016
Ultragenyx Pharmaceutical announced that the FDA has accepted its Investigational New Drug (IND) application for UX016, an experimental small-molecule prodrug for GNE myopathy (GNEM). A phase I/II clinical trial for UX016 is expected to begin in the latter half of 2026, aiming to assess its safety, efficacy, and pharmacokinetics in adult GNEM patients. The company currently holds a Zacks Rank #3 (Hold) and has four other approved therapies on the market.
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action ...
Kahn Swick & Foti, LLC (KSF) has announced a class action securities lawsuit against Ultragenyx Pharmaceutical Inc. (NasdaqGS: RARE), with an application deadline of April 6, 2026, for investors affected between August 3, 2023, and December 26, 2025. The lawsuit follows a significant drop in Ultragenyx's share price after the company announced in December 2025 that its Phase 3 Orbit and Cosmic studies for setrusumab in osteogenesis imperfecta failed to meet their primary endpoints, leading to a decision to reduce expenses. Investors who suffered losses during this period are encouraged to contact KSF.
Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit against Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE) on behalf of investors who purchased securities between August 3, 2023, and December 26, 2025. The lawsuit alleges that Ultragenyx made misleading statements regarding its drug setrusumab's effects on Osteogenesis Imperfecta patients and failed to disclose risks related to its Phase III Orbit study results. Investors have until April 6, 2026, to file a lead plaintiff motion.
RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) investors, encouraging those who purchased shares between August 3, 2023, and December 26, 2025, to join a class action lawsuit. The lawsuit alleges that Ultragenyx made misleading statements about its drug setrusumab's potential, particularly regarding its Phase III clinical trials, leading to a significant stock price drop after negative results were announced on December 29, 2025. The deadline to seek lead plaintiff appointment is April 6, 2026.
Investors in Ultragenyx Pharmaceutical Inc. Should Contact
Levi & Korsinsky, LLP has filed a class action securities lawsuit against Ultragenyx Pharmaceutical Inc. (RARE) on behalf of investors who suffered losses due to alleged securities fraud between August 3, 2023, and December 26, 2025. The lawsuit claims that Ultragenyx made misleading statements regarding the potential of its drug setrusumab, particularly concerning its Phase III Orbit and Cosmic studies, which failed to meet their primary endpoints, leading to a significant stock price drop. Investors have until April 6, 2026, to request to be appointed as lead plaintiff.
Ultragenyx (RARE) wins FDA IND clearance, plans UX016 Phase 1/2 GNE myopathy trial
Ultragenyx Pharmaceutical Inc. announced that the FDA has cleared its Investigational New Drug (IND) application for UX016, a small molecule prodrug for GNE myopathy. This clearance allows Ultragenyx to proceed with a first-in-human Phase 1/2 study, which will be externally funded by a patient group and is expected to begin in the second half of 2026. The study will enroll approximately 24 adults to evaluate the safety, efficacy, and pharmacokinetics of UX016 in treating this rare inherited neuromuscular disorder.
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy
Ultragenyx Pharmaceutical Inc. announced that the FDA has cleared its Investigational New Drug (IND) application for UX016, a sialic acid prodrug aimed at treating GNE myopathy (GNEM). This rare neuromuscular disorder currently lacks approved treatments. The UX016 program is externally funded, with a Phase 1/2 study expected to begin in the second half of 2026 to evaluate its safety and efficacy in adults with GNEM.
Assenagon Asset Management S.A. Has $4.59 Million Holdings in Ultragenyx Pharmaceutical Inc. $RARE
Assenagon Asset Management S.A. reduced its stake in Ultragenyx Pharmaceutical Inc. by 21.0% in Q4, now holding 199,720 shares valued at $4.59 million. Despite institutional ownership of 97.67% and a "Moderate Buy" consensus rating from analysts, the company faces risks including mixed quarterly results—revenue beat estimates but EPS missed—significant insider selling, and ongoing securities litigation. Ultragenyx, specializing in therapies for rare genetic disorders, reported Q4 revenue of $207.28 million, a 25.5% increase year-over-year, but missed EPS estimates with a loss of $1.29 per share.
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) for alleged securities fraud. Investors who purchased Ultragenyx securities between August 3, 2023, and December 26, 2025, are encouraged to contact the firm before April 6, 2026, to participate. The lawsuit claims Ultragenyx made misleading statements regarding its drug candidate for Osteogenesis Imperfecta, which failed to meet a statistically significant reduction in fracture rates during its Phase III ORBIT study.
INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - RGRD Law
Robbins Geller Rudman & Dowd LLP has announced a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025, and suffered substantial losses, have until April 6, 2026, to seek appointment as lead plaintiff. The lawsuit alleges that Ultragenyx made false and misleading statements regarding the efficacy of its drug setrusumab in treating Osteogenesis Imperfecta, particularly concerning its Phase III Orbit and Cosmic studies, which ultimately failed to achieve statistical significance.
INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. (RARE)
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) for alleged violations of the Securities Exchange Act of 1934. The lawsuit claims that Ultragenyx made false and misleading statements regarding the efficacy of its drug setrusumab for Osteogenesis Imperfecta and failed to disclose risks associated with its Phase III Orbit and Cosmic studies, which ultimately did not achieve statistical significance, leading to significant stock price drops. Investors who purchased RARE common stock between August 3, 2023, and December 26, 2025, have until April 6, 2026, to seek appointment as lead plaintiff.
RARE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Investors of Securities Class Action Deadline on April 6, 2026
Faruqi & Faruqi, LLP is reminding investors of Ultragenyx (NASDAQ: RARE) about the April 6, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Ultragenyx made misleading statements regarding the effectiveness of its setrusumab treatment for Osteogenesis Imperfecta and failed to disclose risks associated with its Phase III Orbit study. Investors who purchased Ultragenyx securities between August 3, 2023, and December 26, 2025, and suffered losses are encouraged to contact the law firm.
Vanguard disaggregates Ultragenyx holdings (NASDAQ: RARE) after realignment
The Vanguard Group has filed an Amendment No. 10 to a Schedule 13G/A for Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), indicating a disaggregation of holdings following an internal realignment. This amendment reports zero beneficial ownership for Vanguard and states that certain subsidiaries will now report their ownership separately, as permitted by SEC Release No. 34-39538. Investors are advised to consult future subsidiary filings for details on potential holdings.
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has issued a notice regarding a class action securities lawsuit against Ultragenyx Pharmaceutical Inc. (NasdaqGS: RARE). The lawsuit, filed on behalf of investors who suffered losses between August 3, 2023, and December 26, 2025, alleges securities fraud after the Company's Phase 3 Orbit and Cosmic studies for setrusumab failed, causing a significant drop in stock price. Investors affected have until April 6, 2026, to apply for lead plaintiff status.
ULTRAGENYX DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL,
The Rosen Law Firm is encouraging Ultragenyx Pharmaceutical Inc. investors who suffered losses exceeding $100K during the Class Period (August 3, 2023, to December 26, 2025) to secure counsel before the April 6, 2026, lead plaintiff deadline for a securities class action. The lawsuit alleges that Ultragenyx made misleading statements regarding its setrusumab drug for Osteogenesis Imperfecta, claiming it would decrease fracture rates, despite its inability to demonstrate such a link in trials, causing inflated stock prices. Investors are advised to contact the firm to join the class action.
[ARS] Ultragenyx Pharmaceutical Inc. SEC Filing
This article announces an ARS SEC filing by Ultragenyx Pharmaceutical Inc. (RARE) on March 27, 2026, indicating a low impact and neutral sentiment. It provides details on the filing, including its availability as a PDF document, and lists recent news and other SEC filings related to the company. The article also includes key stock data for Ultragenyx, such as market capitalization and industry.
RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc.
The Gross Law Firm has issued a shareholder alert for Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) regarding a securities class action lawsuit. Investors who purchased shares between August 3, 2023, and December 26, 2025, are encouraged to contact the firm, as the company is accused of making misleading statements about the potential of its drug setrusumab. This follows a significant stock price drop after Ultragenyx announced on December 29, 2025, that its Phase III Orbit and Cosmic studies did not meet primary endpoints.
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline For Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has notified investors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) about a class action securities lawsuit. The lawsuit seeks to recover losses for investors who allegedly suffered damages due to securities fraud between August 3, 2023, and December 26, 2025. The deadline for investors to apply to be lead plaintiff in the lawsuit is April 6, 2026, following a significant drop in Ultragenyx's stock price after the announcement of failed Phase 3 clinical trials for its drug setrusumab.
Ultragenyx Pharmaceutical (NASDAQ:RARE) Upgraded to "Strong-Buy" at Truist Financial
Truist Financial upgraded Ultragenyx Pharmaceutical (NASDAQ:RARE) to a "strong-buy" rating. This upgrade comes amidst mixed analyst ratings and recent downward revisions in price targets from other firms. The company's stock shows notable insider selling activity, while hedge funds have been adjusting their positions.
RARE Investor Alert: Ultragenyx Pharmaceutical Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit
Robbins LLP has filed a class action lawsuit on behalf of investors who purchased Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023, and December 26, 2025. The lawsuit alleges that Ultragenyx misled investors regarding its Phase III Orbit and Cosmic studies for setrusumab. The company's stock price dropped significantly after it announced that these studies did not achieve statistical significance for their primary endpoints.
RARE Investor Alert: Ultragenyx Pharmaceutical Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit
Robbins LLP has filed a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) on behalf of investors who purchased shares between August 3, 2023, and December 26, 2025. The lawsuit alleges that Ultragenyx misled investors about the efficacy of setrusumab in its Phase III Orbit and Cosmic studies, stating the drug would decrease fracture rates in Osteogenesis Imperfecta patients when it did not achieve statistical significance. Following the announcement of study failures, Ultragenyx's stock price dropped by approximately 42.32% in a single day.
RARE Deadline: RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit
The Rosen Law Firm reminds purchasers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023, and December 26, 2025, of the April 6, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Ultragenyx made misleading statements about its Phase III Orbit and Cosmic Studies for setrusumab, particularly regarding its ability to decrease annualized fracture rates in Osteogenesis Imperfecta patients. Investors who purchased during the Class Period may be entitled to compensation.
Lost Money on Ultragenyx Pharmaceutical Inc.(RARE)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a class action securities lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) on behalf of investors who suffered losses due to alleged securities fraud. The lawsuit claims that Ultragenyx made misleading statements regarding the potential of its drug setrusumab, particularly its Phase III Orbit and Cosmic studies. Investors have until April 6, 2026, to request to be appointed as lead plaintiff.
Lost Money on Ultragenyx Pharmaceutical Inc.(RARE)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has announced a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) for alleged securities fraud between August 3, 2023, and December 26, 2025. The lawsuit claims Ultragenyx disseminated misleading statements regarding its drug setrusumab's potential, leading to a significant stock price drop after Phase III studies failed to meet primary endpoints. Investors who suffered losses have until April 6, 2026, to seek lead plaintiff status.
Why Ultragenyx (RARE) Is Down 14.4% After Positive Phase 3 DTX301 Gene Therapy Results
Ultragenyx (RARE) shares dropped 14.4% despite positive Phase 3 data for its DTX301 gene therapy for OTC deficiency, which showed a significant reduction in ammonia and an acceptable safety profile. The article attributes the decline to investors focusing on the company's substantial annual net loss, high R&D spend, and the need to balance an expanding pipeline with achieving profitability, rather than just the promising clinical results. Continued high R&D and potential approval delays remain key risks for the biotech firm.
